Although we did not observe a single false-positive case with a T2/FLAIR-mismatch sign in this large series of over 400 adult patients with newly diagnosed glioma—which is in line with the lower-grade glioma studies from Patel and Broen et al.5,6—a recent study reported contradicting findings.28 Specifically, Juratli et al.28 reported a relatively low specificity of only 76%, with however a relatively high sensitivity of 73% for identifying IDH-mutant (1p/19q non-codeleted) lower-grade gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.